STAAR Surgical Company (STAA) Earnings Call Transcript
May 13, 2026
Earnings Call Speaker Segments
Thanks, operator. Good afternoon, and I appreciate everyone joining us today. With us on this call are Warren Foust, our Interim Co-CEO, President and Chief Operating Officer of STAAR Surgical, along with Deborah Andrews, Interim Co-CEO and Chief Financial Officer of STAAR Surgical. Earlier today, we issued a press release and Form 8-K covering our first quarter 2026 results. Both the results release and the shareholder letter are now available on our investor website at investors.staar.com. This call is set to run for 1 hour, and it will feature Q&A for publishing analysts. Those participating via webcast may also submit questions for today's Q&A session by emailing ir@staar.com. Before we begin, please note that forward-looking statements will be made during today's call. Such statements carry risks and uncertainties that could lead actual results to differ materially from what those forward-looking statements express or imply. I urge you to review the disclosures in today's release, as well as those in our SEC filings. Other than as the law requires, STAAR undertakes no duty to update these forward-looking statements for future events or actual outcomes. Also, in today's discussion, we will mention certain non-GAAP financial measures, such as adjusted EBITDA and constant currency sales. Definitions and reconciliations of non-GAAP metrics can be found in today's release. For the sake of brevity, and unless stated otherwise, every comparison made on today's call is year-over-year against the corresponding period. One last quick note. We plan to use our website to disclose material nonpublic information and to satisfy our disclosure obligations under Regulation FD. Those disclosures will appear in the Investor Relations section of our website. As a result, investors should keep an eye on our investor website, in addition to tracking our press releases, SEC filings, public conference calls and webcast. With that, I'll hand the presentation over to Interim Co-CEO Warren Foust. Warren?
Hello, everyone, and welcome this afternoon. Deborah and I are glad to spend time with you again and share how things have gone during the roughly 100 days since we took over as interim co-CEOs. It's a pleasure to discuss the first quarter of 2026, since we've mostly put behind us the difficulties encountered in 2025 — among them major turbulence caused by the possible Alcon merger, too much channel inventory in our biggest market, and the threat of higher tariffs. Those problems are now resolved. Let's move on to Q1. We believe the beginning of the year has gone quite well, and you can see that in what we reported for the first quarter. I'd highlight that we executed solidly throughout the company and that momentum kept building across our main markets generally. Considerable progress was achieved toward our central goals — especially when it comes to growing revenue and broadening our profitability. Those efforts stay at the top of our priorities, along with the work of bolstering what we offer in our product lineup and building out the pipeline for the generations ahead. During the first quarter, net sales grew impressively on both a sequential basis and compared with the same period a year earlier. Profitability also showed a notable gain in that quarter, as adjusted EBITDA moved into positive territory. Several factors fueled these results: outstanding performance in China, a record quarter in the U.S. exceeding $6 million for the first time, and healthy gains across all 3 of our regions. Another milestone worth celebrating is that worldwide ICL sales have now passed 4 million units. Our dedicated teams and distribution partners worldwide deserve recognition for the revenue growth they're delivering. Meanwhile, disciplined spending and focused execution continue to lift our profitability. These results strike me as an early sign that our strategy is starting to deliver. Alongside the financial numbers, this quarter brought a number of key business milestones that strengthen our conviction in STAAR's long-term potential. To start, we've achieved additional milestones in bringing EVO+ ICL to market in China, and we've started delivering substantial quantities there. Next, as we kicked off Q1, our inventory position in China had returned to normal and matched the levels we'd agreed to in our contracts, and we managed to increase sales while keeping stock steady or even trimming it a bit over the quarter. Then, our production site in Nidau, Switzerland keeps expanding, and by 2026 it's set to provide all EVO and EVO+ lenses delivered to China free of import duties. Lastly, we're moving ahead with implementing our new Oracle ERP system, causing minimal interruption to operations so far, and we anticipate gains in transparency, alignment, and ability to scale as time goes on. Taken as a whole, these achievements matter since they underpin our ability to execute in the short run while also positioning us to grow the business more efficiently over the long run. I'll turn now to China, the biggest factor behind our first quarter results and still a major area of emphasis for STAAR. Within China, our Q1 results showed that we kept picking up share in premium lens-based refractive surgery. The key messages landed clearly: we're still building momentum with EVO ICLs, EVO+ ICLs are off to a healthy start, inventory has returned to typical levels, we have better line of sight further into the channel, and market conditions have grown more stable. In China, the refractive environment in Q1 came across as less volatile than what we experienced during the rocky period spanning 2022 through 2024. The macro picture is still uneven, yet judging by what we observe and what customers tell us, demand for refractive procedures keeps expanding at a moderate rate. We take encouragement from how our team performed in Q1 and from the early reaction to EVO+, a significant milestone in our innovation roadmap, where robust surgeon adoption and clinical differentiation have already pushed our Swiss manufacturing site to produce more. Looking ahead, we stay committed to disciplined execution and to carrying this momentum through the year, while keeping a careful eye on macroeconomic factors in the market; turning now to the United States, we are pleased that first quarter sales there came in above $6 million, and we still see this market as a key long-term growth opportunity for STAAR. In addition, we obtained FDA approval that broadens the EVO ICL indication to patients between the ages of 45 and 60, which enlarges our addressable market further. Net sales climbed 22% year-over-year even as laser vision correction procedures requiring removal of corneal tissue remained sluggish. Growing adoption of EVO ICL strengthens our conviction that refractive surgery's future is predominantly lens-based. Our results, in our view, reflect more surgeons coming on board, tighter commercial execution, and marketing that is better focused on accounts that are incorporating EVO ICL more deeply into their refractive portfolios. Relative to markets where ICL is more established, penetration in the U.S. remains low, so we continue to view that country as a major opportunity for growth over the long term. Outside of China and the U.S., several markets faced disruption tied to geopolitics and trade in the quarter, particularly certain areas of the Middle East. The effect on net sales came in under $2 million. Along with broader macroeconomic uncertainty across Europe and portions of Asia, we are monitoring these situations closely. We likewise keep seeing appealing long-term opportunities in markets like India, though near-term price sensitivity and macro volatility call for a measured approach. More broadly, as we chase global growth opportunities, we remain disciplined about allocating capital and resources. We are putting priority on markets and commercial programs showing the greatest potential, while still gaining from the cost reduction efforts we began in 2025. As sales increase, we expect this approach to bolster operating leverage going forward. On the whole, our view has not changed. The worldwide move toward lens-based refractive surgery stays a meaningful long-term growth driver for STAAR. Taken together, these changes reflect the commercial and operational strides we're making, while keeping the rigor needed to deliver steadier results over the long run. With that, I'll pass it over to Deborah, who will take us through the financials in greater depth. Deborah?
Thank you, Warren. Results for our first quarter show solid execution on both the top line and profitability fronts, which aligns with the framework we laid out in the shareholder letter for our fourth quarter. Net sales came in at $93.5 million, up 119.6% compared with a year earlier, powered by robust China sales along with double-digit growth in the Americas. China net sales reached $47.4 million during the first quarter, fueled by the commercial launch of EVO+ as well as ongoing demand for EVO. Distributor inventory stayed comparable to levels at the end of 2025 and within the range we target to properly serve the refractive market. When you look beyond China, our net sales were up 6%, and we view that as a solid result considering what's happening in the broader economy. During the first quarter, we benefited from a strong performance in the U.S. market, even though laser vision correction there continued its downward trend — gains that were partly counterbalanced by macroeconomic and geopolitical pressures in the Middle East and India. On the adjusted EBITDA line, we posted $24.4 million, compared with a loss of $26.3 million on the same basis a year earlier. That swing came from stronger net sales, better gross profit, and the payoff from cost actions taken since 2025. Operating leverage is beginning to show up, which aligns with the trajectory we've laid out toward lasting profitability. For Q1 2026, our gross margin came in at 73.6% of total net sales, up from 65.8% during the same quarter a year earlier. Several factors drove that year-over-year gain: we no longer carry period costs tied to ramping up manufacturing in Switzerland, advanced manufacturing expenses came down, inventory provisions were lower, and freight plus other cost of sales shrank as a share of sales. Partly working against those gains were higher manufacturing costs per unit, which stemmed from reduced production volumes in 2025. Operating expenses totaled $60.9 million in the first quarter of 2026, versus $85.4 million in the comparable prior year quarter. When you strip out restructuring and merger-related costs, our operating expenses came in at $51.5 million, down from $62.7 million in the same quarter last year. That's an 18% year-over-year decline, and it shows the impact of the cost reduction efforts we kicked off in 2025 along with our ongoing discipline around spending. We're still on track to hit our 2026 spending target of $225 million. For the first quarter of 2026, operating income was $8 million, versus a loss of $57.4 million in the prior year quarter. Net income for the first quarter of 2026 came to $5.2 million, or $0.10 per diluted share, compared with a net loss of $54.2 million, or $1.10 per diluted share, in the same quarter a year earlier. The main reason net income improved compared with a year earlier was that we earned more gross profit while spending less on operations, which shows we can increase net sales and still stay disciplined about costs; when the quarter closed, we held $163.9 million across cash, cash equivalents and investments available for sale, and we owed nothing on debt. Looking at it quarter to quarter, cash came down relative to the fourth quarter of 2025, largely because of expenses such as seasonal bonuses and other employee incentives, global sales meetings, severance, and costs tied to the cooperation agreement with Broadwood Partners. With those items now behind us, we expect cash to build through the remainder of the year. Overall, the profit and operating leverage delivered in our first quarter results leave us encouraged. Our attention stays on weighing expansion against careful investment and on keeping financial flexibility intact. Having said that, I'll hand the call back to Warren. Warren?
Thanks, Deborah. In summary, the first quarter came in strong, showing how far we've come in creating a more robust STAAR through distinctive technology, tighter operational control, and a more defined route toward lasting growth and profitability; in our view, STAAR stands in a better place now than when this year began. During the quarter, we delivered solid growth, a return to profitability, better adjusted EBITDA margins, and gains on the operational front. We brought EVO+ ICL to market in China, moved our Swiss manufacturing capabilities forward, kept up the rollout of our Oracle ERP, and reinforced our cost structure. Meanwhile, the opportunity ahead over the long term stays highly attractive. STAAR holds distinctive polymer material along with advanced optical technology in EVO ICL. On top of that, we observe rising adoption worldwide in a sizable market, backed by expanding myopia prevalence and a move toward lens-based refractive surgery; at this point, our aim is to extend this momentum in line with our key objectives, revenue growth, expanding profitability, and advancing innovation. Deborah and I stand together with our Board and remain dedicated to long-term value creation via clear priorities and operating discipline. We appreciate your ongoing support. Operator, we're ready to begin the question-and-answer session.
John, thank you for asking, and I appreciate both of your questions. Yes. So, we get why you're looking for guidance. Q1 has traditionally been a very solid quarter, and the results we delivered in Q1 are something we take pride in. However, looking back, there has been a pattern where the peak season might not materialize, as seen between 2022 and 2024, when conditions were somewhat weaker. So while we feel positive, at this moment we aren't prepared to declare, "We have full confidence in whatever lies ahead, given all the macroeconomic and geopolitical developments, not only in China but in other regions as well." There are a couple of wars underway, and a few currency-related difficulties in different markets. Therefore, we aren't ready to make that call, which means I'm unable to provide any guidance on that $311 million to $312 million figure. On the China side — well, you've probably seen what our largest customer in that region has been saying: conditions in the refractive market look steadier than they have in a while. That matched what we observed as 2025 came to a close. Through Q1, we're happy with our position so far. We'll wait and see what the peak season delivers, though if it does arrive, we'll definitely be prepared.
Congrats on all the headway you've been making. I realize you aren't providing guidance at the moment. That said, I wanted to start by bringing up that consensus going into the print stood at $311 million, and then $312 million. Does that number sit well with you? Following up on China: how confident are you about the peak season in Q2, considering how well Q1 has gone so far? And should we think of China revenue staying level from one quarter to the next as a reasonable expectation for Q2? A (Warren Foust):
Nice work on the numbers. I want to kick things off with the competitive situation in China. Warren, could you perhaps describe what you're observing there regarding competition from iBright? In the 12-plus months since it entered the market, how large has it become? Also, what do you anticipate going forward concerning iBright's effect, plus the possibility of more China phakic IOLs coming down the pipeline? Then I have one more question after that.
Sure. Tom, I appreciate you asking. Honestly, we're fans of having rivals out there. It only reinforces our belief that lens-based refractive surgery represents the future — that's precisely what it is, lens-based — and we're positioned to benefit. So competition is welcome. When it comes to iBright, we're aware of them. We're also aware that a few implants took place in the early days. My sense is that surgeons are likely being cautious. There's no toric version on the market. That means it's a steer-only lens. We hold them in respect as competitors, yet up to this point, it has simply been — it has been a nonissue for us.
Understood. That's really useful. Now I'll try my hand at the revenue outlook. From what I can tell, 1Q appeared to be an ordinary quarter in every respect, especially when it comes to inventory; as a matter of fact, I believe you said it declined on a sequential basis. So what I want to ask is whether it's reasonable for us to treat 1Q as a clean starting point and apply the usual seasonality of the business when thinking about 2Q and beyond. For 2Q in particular, as you noted, it typically experiences a fairly substantial sequential increase fueled by China. Is there any reason that wouldn't happen? And really, the core of what I'm asking is whether 1Q is more or less a clean base from which we can model the remainder of the year on reps?
Yes, absolutely. Perhaps I'll begin, and then I'll ask Deborah to finish up the remarks. Look, we're aware that a year ago, there was some pull forward during the first quarter related to military procedures and that sort of thing. We aren't involved in those procedures in China, but there could be something of a halo effect when clinics go out and recruit for these patients to visit their clinics. And certainly, those patients who might turn out to be candidates for EVO ICL could receive it. So we'll find out whether that repeats as we head into the second quarter. When it comes to seasonality, students will still graduate from college. Their parents will still want them to stop wearing glasses and contacts. Those individuals who could become patients will weigh their options. And we believe, and observe, that more and more people are selecting EVO ICLs; what that will mean from a seasonality perspective is difficult to predict. It's accurate that June and July tend to be stronger months, based on historical patterns, but we simply can't yet say that we believe that will hold true. Once again, the strength in Q1 is genuine. Let's see what Q2 delivers; but Deborah, anything else you'd like to add?
No. My sense is that we feel good about what's ahead. A solid second quarter is what we're anticipating. As for what Q3 will bring, that hasn't been determined at this point. So when it comes to offering guidance or anything of that nature, we're somewhat hesitant, at least over the near term, and we'll take another look at that further into the year.
Regarding your point about this being the initial quarter without complications—well, 2025 brought plenty of disruption, and that extends back to late 2024, tied to what occurred with inventory plus when we recognized revenue and when we recognized the related COGS. As I mentioned during my prepared remarks, every one of those issues has now cleared out of the system. That makes end market demand—which truly matters, and we track it carefully—something we described at the close of 2025 as falling within the mid-single-digit range. Today we've stated, and I believe we've observed with IR and others who've reported as well, that the refractive market in China appears relatively steady; now, does that mean all of us are genuinely thrilled about it? I'd like to see the refractive market keep expanding. What does excite us is that EVO appears to be gaining share within a refractive market where laser vision correction requiring removal of corneal tissue is kind of falling out of favor.
Perhaps I could just ask a quick follow-up regarding that China figure for Q1. Warren and Deborah, I recall the two of you mentioning that Q4 was somewhat messy because of product returns in the distribution channel, and that this situation was supposed to settle down once the deal closed and that disruption faded. So my question is whether that situation flipped around during Q1. Also, what portion of Q1 China revenue comes from orders placed after the deal to make up for what was missing in Q4? Really, I'm just trying to figure out what a normalized Q1 China run rate looks like. Then I have one more question after that.
All right. Thank you, Simran. Well, inventory comes up in our discussions constantly — if not daily, then certainly weekly. That means we keep a close watch on what end market demand is doing. We therefore understand where inventory stood when we moved into 2026; and when the quarter wrapped up, we delivered a strong result in China, and that stock position among our distributors plus the 2 importers we work with there was equal to or lower than where it was when the year began. That tells us end market demand is behind the sales. So that gives us confidence, and we will keep monitoring it. You can be sure we will stay on top of that.
Additionally, it was good to observe that what we sold to the market came close to what was sold into the market. That is exactly the situation we have hoped for: inventory that stays steady, with our outbound sales roughly matching the sales going in.
Understood. That is quite useful; and regarding EVO+, I believe I caught — assuming I understood what you said properly, you mentioned that initial EVO+ demand was stronger than anticipated in Q1. Could you share anything about what portion of Q1 China revenue came from EVO+? Also, how should we view the volume price mix advantage tied to EVO+ during Q1 and afterward as it begins to scale up?
Right. Well, the response from customers regarding EVO+ has had us thrilled, and that includes not only our surgeons but also consumer enthusiasm for EVO+. So that is great. Keep in mind that every bit of that product originates from our Swiss manufacturing facility in Nidau; and for that, we are currently and have been required to expand that site so it can produce not just V5 but EVO+, and eventually also EVO, the initial iteration, which we refer to as V4c, though for our China customers it is EVO. The truth is we required additional V5 beyond what we had intended to make; so that is a positive situation; we will get that resolved shortly. Therefore we believe we can fully meet the market's requirements by the conclusion of the Q2 period and through the remainder of the year. And through the remainder of the year, we will have ramped up — during the remainder of the year, we ought to be capable of supplying both EVO+ and EVO from our Swiss production site. So all of that is positive. Regarding the proportion, we are not disclosing those figures at this point, but I — what I can tell you is we understand that the marketplace has embraced and accepted the higher price that EVO+ commands. And that is a positive development. It also indicates there will keep being — customers in China have pursued a pricing approach that lets them provide a more premium EVO+, while still selling a higher priced premium EVO, and that aligns with our other refractive products. Consequently, you will not observe a complete shift strategy toward V5 to EVO+. What you will observe is surge customers continuing to use that product as their top-tier offering.
Nice quarter — congratulations on that. Perhaps I can ask something further about China, looking at it from 2 directions. First, regarding Aier Eye Care Group specifically: several years ago, when we examined procedure volumes in China, I believe that before the correction, roughly 50% of those volumes were being accounted for by Aier. So I'd like to verify what Aier's position is now. Also, how much visibility do we have into their backlog of procedures in particular? Then I have one brief follow-up.
Sure, Anthony, that's a fair question. It isn't really that high. I don't believe we've disclosed the precise figure. So I'll leave it at that. That said, Aier continues to be a very significant, very key customer for us in China. We have tight working ties with them locally through our direct STAAR employees, and we also have tight working ties with them via our importer. Thus we stay close to them at all times. They appear to have a strong desire to keep a premium offering going; they have a strong desire for EVO+, but we — the strong quarter we had was truly fueled by ongoing uptake of EVO at mid- and high diopters; and so I think they keep running a well-rounded business. It represents a significant piece of our current and our future business in China, and our relationship with them is extremely strong.
Then a quick follow-up regarding how distributors are behaving. Since we can see less clearly than during earlier years, and we're heading into the busier stretch across 2Q and 3Q, clarity remains somewhat constrained. These days, what quantity of stock ought distributors to keep on hand? Also, do the 2 distributors operating in the market roughly sit where they ought to, given the level of end market demand? I'll rejoin the queue.
Yes, that's an excellent question. As we've stated, 6 months represents the period covered by our contractual arrangements with both importers, and we currently sit at or beneath that mark. Consequently, when 2024 came to a close, we were considerably above those thresholds. Throughout 2025 we worked those levels down, which was painful, and by the September time frame we completed that effort, and since then we've monitored it carefully. Naturally, demand in the end market stays the main force determining whether inventory rises or falls; however, as Deborah mentioned before, sales across the 2 markets now align much more tightly with the end market demand we observe; therefore we can see end market sales. It comes down to logistics; we've shared a great deal of disclosure on this. Yet when we reference end market sales, what we mean is the logistics, the shipments leaving our importers headed downstream toward sub distributors and, frequently, straight to hospitals, minus any returns. That provides us a solid estimate of what truly occurs in the market; and provided we keep holding inventory at the level we began with, roughly 6 months, we remain confident that we grasp well what end market demand is doing.
I'm going to stay on this same subject. My apologies, since I believe it matters a great deal. When I examine the consignment figures for this quarter and the prior one, and consider them against the historical backdrop, I want to grasp your thinking on it, because with consignment still running higher, I'm curious how much of that stems from your distributors — perhaps some of that inventory specifically returning and shifting into consignment? Then the real question: historically we've witnessed a 1Q to 2Q step up. Whether you're committing to that, I can't say. Without the guidance I can't tell, because, once more, in a normalized environment you ought to see a step-up from 1Q to 2Q given seasonal dynamics, thanks to the busy season. But at present, the street isn't modeling that; so I'm wondering if you could help me think through how those 2 fit together a bit more closely. This may repeat what's already been asked, but it's important, obviously.
Well, obviously, Q1 was very, very strong for us and was probably even, frankly, a touch beyond what we expected, to be very honest with you. So our natural question is, will this duplicate in Q2? That's the big question. We're anticipating a solid second quarter, given that it marks the beginning of the peak summer period. As for whether it ends up matching last year precisely or lands slightly higher, we haven't issued any forecast on that yet. It's simply not something we're projecting right now. Then when we get to Q3, it's possible the seasonal tendencies shift somewhat compared with what we've seen in past years. That means we genuinely need to — well, Q1 came in strong for us, and I'd call it a clean Q1. At this point we're hoping to carry that same momentum through Q2 and Q3, which would let us — which would put us in a position to give you all guidance on a more accurate footing.
Absolutely, and regarding consignment stock, Ryan, I appreciate you raising that. So, we do have certain consignment arrangements globally, outside of China, that assist us in keeping service levels up for our operations. We actually established a consignment on just 2 separate occasions — one shipment into China, aimed at sidestepping the tariff hit back when those were extremely high, if you recall, tariffs above 100%. We proactively sent product into China so it could be stored with our importers, though this wasn't a shift toward a consignment model. It was more of what I'd describe as a bridging quantity of inventory. We don't refill it. As a result, that consignment is gradually diminishing as it gets drawn down, and for service levels we depend on our importers carrying their own stock. So when we discuss inventory positions, it's a like-for-like comparison that we needed — our contracts with distributors obligated them to keep 6 months of stock on hand to sustain service levels. This is well documented, and we drifted far beyond that. We brought it back in line by September of last year and have kept it there since. That remains the case for Q1 as well. So I wouldn't lump the consignment, especially the one in China, together with any of those figures.
All right, moving on to my next question.
By the time this year wraps up, we expect that to be operational.
Please, Deb, go ahead. My apologies — I didn't intend to cut you off. What would you need to observe before you'd offer guidance? I suppose what I'm asking is, which measurements would you point to and conclude, alright, at this point we can see where our business is headed? Since from our vantage point, it isn't obvious what's preventing you, especially after the results from 1Q, which were plainly strong.
Right. As I've mentioned previously, I understand the desire for it; that logic is completely sound. And we would be delighted to provide it. We attempted to share certain insights, especially regarding OpEx, and we've even offered remarks about gross margin and similar items. Under the present setup, we've now been operating for 4 months. Considerable headway has been made, without question. The strength in Q1 is genuine. We simply encountered the reality of all the events unfolding globally. Plus the fact that other companies have stood here and declared, "Hey, Q1 was great, let's beat and raise and then give guidance." And afterward we observed how that played out. So we're happy with Q1. We're enthusiastic about Q2, yet we're merely not ready at this point to provide it. The moment we believe there's sufficient stability for us to forecast with accuracy — because getting it right matters to us. The moment we believe we possess sufficient information to forecast accurately on your behalf is what we would require in order to supply it.
I apologize for dwelling on Q2 again. I simply wanted to ask a follow-up, Deborah, regarding a few things you mentioned. I believe your comment was along the lines of anticipating a solid 2Q. So I am just attempting to grasp whether that mirrors patterns you are observing in April and somewhat into the first part of May, even setting aside figures, like anything qualitative you might share or discuss, concerning how Q2 is developing compared with what we observed in Q1?
What I would say is that Q2 is developing the way I would anticipate for a typical Q2 given historical patterns.
All right, that's great. So perhaps regarding pricing specifically — it seems like globally it declined by roughly high single digits. Is that purely a matter of geographic mix, or is there something worth mentioning? And on a region-by-region basis, what are you observing when it comes to pricing?
Yeah, appreciate that question. Pricing pressure exists everywhere around the globe. I believe our leaders at the country level have performed quite well in their efforts to maintain pricing and secure value for what's being provided — restoring sight for patients who are seeking it — so we take pride in those efforts. Occasionally there are subtleties tied to the mix between toric and sphere. That's something we monitor. Without question, we are seeing a price increase — a lift — in China thanks to the EVO+ launch, and that will assist us globally once you begin averaging out ASPs. Then across different markets, when our customers begin moving along the adopter curve and opt for lens-based refractive technology rather than laser-based approaches that involve removing corneal tissue and aren't reversible, those customers attempt to exert pressure on us regarding price; so the expectation is that wherever we trade on price, it's done in return for greater volume, though it remains something we watch very carefully.
There's been plenty of questions on China specifically. And I believe you've been clear that no additional insight is something you intend to offer there. But what I wanted to ask is whether you'd be open, at minimum, to sharing a few more thoughts on what you expect for growth in the business excluding China during 2026? And then, I suppose, for my second follow-up, can you put a number on what the expanded age range indication contributes for EVO in the U.S.?
Mason, perhaps I'll take the second one first. The size of the opportunity has been quantified by us. Trying to pin down precisely how much you capture from it, I think, is a tougher exercise, particularly in the first quarter when the updated labeling came through — something we're excited about. It aligns with the majority of labeling we've had globally. Our regulatory team is awesome, and they've done a great job going market-by-market to ask, "Hey, where can we capitalize on reaching more patients, the potential to get EVO through our labeling?" Whether that means going down in age, whether it means changing the cylinder, whether it's simply going down in the doctor that's approved in that market. So kudos to that team. It probably unlocks a universe of 8 million additional potential patients; how many of those we can tackle over the coming year and years, we'll see, but we know it opens up. And it opens up more conversation around what options exist for patients; so there's that. And then the first question, I'm sorry?
What about growth expectations if we set China aside?
Setting China aside. Well, what we're seeing is that we stay hopeful, especially regarding the value this business holds over the long haul when it comes to the chance to grow. Consider merely what's going on in refractive surgery along with that slowness I mentioned regarding the U.S., plus the movement we're observing away from laser vision correction being the main choice. Surgeons, customers, and practices — based on how they're configured in various parts of the world and are committed to providing refractive technologies — need to include EVO ICL among their offerings so they can serve as a full-service refractive surgeon. That's thrilling when it comes to what lies ahead for this business over the long term. So what part will ex-China play in the near term? Strong growth from key markets keeps coming our way. Take Japan — what's occurred there makes us proud. Take the U.S. — that market is expanding, and it's one we kind of quit discussing, and our confidence in the U.S. as a long-term growth driver remains, yet 22-plus percent growth there following a robust prior year, and that figure is turning into something more respectable now; previously it was high growth on low volume, and we still want to expand that volume considerably, but we take pride in that market and in others. We'll continue battling and give it our best effort. Still, my belief is you'll witness growth broadly throughout the business.
We've seen increases in basically all geographies apart from the Middle East and India. That impacted us, and because of it, growth outside China came to just 6%. Still, that 6% is a strong figure, which is great, and it remains in the mid-single-digit range. So should conditions ease in those remaining countries, in those other markets, there's a chance it could come in above that level.
Nice work on how the year has begun. I'll limit myself to just one question. Deborah, mine is about the P&L, since I don't believe that topic has come up in the Q&A so far. Your OpEx discipline this quarter was really impressive. My understanding is that the FY '26 spend target sits at $225 million, and I was hoping you might offer a bit more detail on how that spend is expected to be paced across quarters in the model. Then, regarding gross margin, perhaps I simply missed this in the prepared remarks, but could you remind us what trend you're anticipating for gross margin this year?
Sure. Our gross margin goal for this year was roughly 75%. We understood we would come in below that. My hope is that we finish the year — or at minimum finish the year — at that level. Still, we do face some headwinds, including a higher cost of inventory moving through the P&L, items like that, and larger inventory provisions tied to expiring product sold during '23 and '24. On top of that, we're raising our volumes substantially at our Swiss facility during the second half of the year. Because of that, improved unit costs should show up in the second half of the year. So my hope is that you'll then see gross margin tailwinds starting in 2027. That said, that figure is the overall gross margin target. On the spending side, our spending tends to be fairly linear, except when trade shows occur. In quarters that include trade shows such as ASCRS or ESCRS, which usually fall in Q2 and Q3, you'll notice a bump in spending. Apart from that — it simply depends. If you multiply out our actual spending this year, it comes in well below a $225 million run rate. So we do anticipate somewhat more DTC and similar items in the quarters ahead; therefore it won't be precisely the same. My expectation is that this will rise from its current level, yet on the whole, hold at that $225 million figure.
Anthony, just a quick follow-up. In the past, you've given us the global growth rate for the refractive market and total refractive surgeries. If we have to break that out globally, we can do the math on where ICL sits. But do you have the figures handy for where we exited April in terms of global refractive surgery growth, and where are you settling versus that?
Yes, thanks Anthony. Those numbers are really muddy. Once you get outside the U.S., outside Western Europe, just a few countries, and outside major markets like China and Japan, it gets quite muddy. Market Scope does a good job, the best they can. IQVIA data does the best job they can. The Refractive Surgery Council in the U.S. would tell you Q1 was down 7%; we grew 22%. Last year, I think they'd say it was down 15%. The China market, who knows? It looks like it was flattish at least for the last year or so; and you see what we're doing in growth. Our growth numbers are sort of gaudy, obviously, because of the low base or no base even in Q1. So that's not appropriate. But I think what we believe is happening is what others have said is happening, including our largest customer, that the market is sort of stable, maybe low single digits, could be even flat and maybe we're getting it out of price with EVO+. It's just too early to tell what's happening there. But I think if you just take a step back and acknowledge the data is dirty, the laser vision correction market is flat to declining in most major markets around the world. Where SMILE has a larger penetration of total laser vision correction procedures, then they grow a little bit. But generally speaking, the refractive market is pulled down by lasers and it's increasing by ICLs.
That wraps up both the Q&A portion and this conference call. We appreciate your participation in today's presentation. You're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete STAAR Surgical Company transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to STAAR Surgical Company earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.